drugset / Trial / NCT00408681
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
NaSingle-groupOpen-labelSupportive care
Summary
RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant.
Timeline
- Start
- 2006-06
- Primary completion
- 2010-11
- Completion
- 2015-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lithium Carbonate | Unknown | — | Oral |
Indications
Burkitt lymphoma
Hodgkins lymphoma
MALT lymphoma
acute myeloid leukemia with 11q23 abnormalities
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
acute myeloid leukemia with t(8;21)(q22;q22) translocation
acute myeloid leukemia, t(16;16)(p13.1;q22)
acute promyelocytic leukemia
atypical chronic myeloid leukemia, BCR-ABL1 negative
blast phase chronic myelogenous leukemia, BCR-ABL1 positive
childhood acute lymphoblastic leukemia
childhood acute myeloid leukemia
childhood kidney neoplasm
childhood myelodysplastic syndrome
chronic eosinophilic leukemia
chronic lymphocytic leukemia/small lymphocytic lymphoma
chronic neutrophilic leukemia
diffuse large B-cell lymphoma
female breast carcinoma
gestational trophoblastic neoplasm
hairy cell leukemia
juvenile myelomonocytic leukemia
large-cell immunoblastic lymphoma
leukemia, myeloid, accelerated-phase
malignant testicular germ cell tumor
mantle cell lymphoma
mycosis fungoides and variants
myeloproliferative neoplasm, unclassifiable
neuroblastoma
nodal marginal zone B-cell lymphoma
ovarian carcinoma
ovarian germ cell tumor
plasma cell myeloma
primary cutaneous T-cell non-Hodgkin lymphoma
primary myelofibrosis
rhabdomyosarcoma
splenic marginal zone lymphoma